129593-44-8

Upstream product

• 141281-58-5 3-Amino-2-(hydroxymethyl)naphthalene 
• 63212-42-0 3-iodo-2-naphthoic acid 
• 93-09-4 naphthalene-2-carboxylate 
• 409369-87-5 methyl 3-iodo-2-naphthoate 
• 5959-52-4 2-Amino-3-naphthoic acid 
• 66-99-9 β-naphthaldehyde 

Downstream Products

• 129593-43-7 2-[4-(tert-Butyl-dimethyl-silanyloxy)-3-(diphenyl-phosphinoyl)-buta-1,2-dienyl]-3-[3-(tert-butyl-dimethyl-silanyloxy)-prop-1-ynyl]-naphthalene 
• 129593-60-8 2-(Diphenyl-phosphinoyl)-4-[3-(3-hydroxy-prop-1-ynyl)-naphthalen-2-yl]-buta-2,3-dien-1-ol 
• 700866-15-5 4-[(3-iodonaphthalen-2-yl)methoxy]phenol 

Relevant academic research and scientific papers

Super-Electron-Donor 2-Azaallyl Anions Enable Construction of Isoquinolines

Herein is introduced the application of “super-electron-donor”(SED) 2-azaallyl anions in a tandem reduction/radical cyclization/radical coupling/aromatization protocol that enables the rapid construction of isoquinolines. The value of this transition-metal-free method is highlighted by the wide range of isoquinoline ethyl amines prepared with good functional group tolerance and yields. An operationally simple gram scale synthesis is also conducted, confirming the scalability.

Palladium-catalyzed intermolecular tandem cyclization reaction: a highly regioselective synthesis of functionalized 3H-spiro[isobenzofuran-1,3′-isochroman] scaffolds

A highly regioselective synthesis of functionalized 3H-spiro[isobenzofuran-1,3′-isochroman] scaffolds using a novel palladium-catalyzed tandem cyclization reaction is explored. During the reaction process, C-O, C-C and C-O bonds are sequentially formed in one pot via decarboxylative allenylpalladium formation, nucleophilic attack, arylpalladium addition and intramolecular nucleophilic attack.

ISO quinoline metal complex and its preparation method and application

The invention discloses a benzoisoquinoline metal complex as well as a preparation method and application thereof. The structural formula of a metal complex containing a benzoisoquinoline structural unit is as shown in a formula I which is shown in the sp

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme

Mechanistic studies of hoveyda-grubbs metathesis catalysts bearing S-, Br-, I-, and N-coordinating naphthalene ligands

Derivatives of the Hoveyda-Grubbs complex bearing S-, Br-, I-, and N-coordinating naphthalene ligands were synthesized and characterized with NMR and X-ray studies. Depending on the arrangement of the coordinating sites on the naphthalene core, the isomeric catalysts differ in activity in model metathesis reactions. In particular, complexes with the Rui￡CH bond adjacent to the second aromatic ring of the ligand suffer from difficulties experienced on their preparation and initiation. The behavior most probably derives from steric hindrance around the double bond and repulsive intraligand interactions, which result in abnormal chemical shifts of benzylidene protons observed with 1HNMR. Furthermore EXSY studies revealed that the halogen-chelated ruthenium complexes display an equilibrium, in which major cis-Cl2 structures are accompanied with small amounts of isomeric forms. In general, contents of the minor forms, measured at 80°C, correlate with the observed activity trends of the catalysts, although some exceptions complicate the mechanistic picture. We assume that for the family of halogen-chelated metathesis catalysts the initiation mechanism starts with the cis-Cl 2a?trans-Cl2 isomerization, although further steps may become rate-limiting for selected systems. Isomerization first: A family of halogen-chelated Hoveyda-Grubbs complexes displays a cis-Cl2a?trans-Cl2 equilibrium in solution. Relative contents of the minor trans forms go along with the activity of the metathesis catalysts, suggesting its participation in the initiation mechanism (see figure). A unique effect of the naphthalene ligands enables control of the activity over a broad range, from moderately achieve to dormant, and was manifested in 1HNMR for complexes with repulsive H×××H intraligand interactions (Mes=Mesityl).

CETP INHIBITORS

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS

Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A1 is a cyclic group, and B is a cyclic group which is attached to the heterocyclic ring directly or through a methylene group.